This pharmaceutical startup has developed a blood plasma substitute using P4P technology, which aims to provide affordable and functional alternatives to traditional blood plasma for patients in need. By increasing access to plasma-derived therapies, the company enhances treatment options and supports the regeneration of the body, particularly for the aging population.
Funding
Funding not disclosed
Founders
Product
Problem
Current blood plasma supplies are limited, and only a fraction of patients who require plasma transfusions receive them. The high cost and scarcity of traditional blood plasma restrict access to life-saving therapies, particularly in developing countries and for patients with rare conditions.
Solution
This startup is developing a blood plasma substitute using proprietary P4P technology to create affordable and functional alternatives to human-derived plasma. The synthetic plasma aims to increase the availability of plasma-derived therapies, enabling broader access to critical treatments for a range of conditions. By offering a cost-effective and scalable solution, the company seeks to address the unmet need for blood plasma and improve patient outcomes. The technology also supports regenerative processes within the body, potentially benefiting the aging population.
Target Audience
The primary target audience includes hospitals, blood banks, and healthcare providers facing shortages of traditional blood plasma, as well as patients requiring plasma transfusions for various medical conditions.
Features
- P4P technology for producing synthetic blood plasma substitutes
- Formulation designed to mimic the functional properties of natural blood plasma
- Scalable manufacturing process to ensure consistent and affordable production
- Potential applications in trauma care, surgery, and treatment of various blood disorders
- Supports the regeneration of the body through Edestin